330 related articles for article (PubMed ID: 34830841)
1. Uveal Melanoma Metastasis.
Rossi E; Croce M; Reggiani F; Schinzari G; Ambrosio M; Gangemi R; Tortora G; Pfeffer U; Amaro A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830841
[TBL] [Abstract][Full Text] [Related]
2. The biology of uveal melanoma.
Amaro A; Gangemi R; Piaggio F; Angelini G; Barisione G; Ferrini S; Pfeffer U
Cancer Metastasis Rev; 2017 Mar; 36(1):109-140. PubMed ID: 28229253
[TBL] [Abstract][Full Text] [Related]
3. How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma.
Marseglia M; Amaro A; Solari N; Gangemi R; Croce E; Tanda ET; Spagnolo F; Filaci G; Pfeffer U; Croce M
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922591
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives.
Croce M; Ferrini S; Pfeffer U; Gangemi R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31216772
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances and Challenges in Uveal Melanoma Immunotherapy.
Fu Y; Xiao W; Mao Y
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804863
[TBL] [Abstract][Full Text] [Related]
6. New Treatment Horizons in Uveal and Cutaneous Melanoma.
Brănişteanu DE; Porumb-Andrese E; Porumb V; Stărică A; Moraru AD; Nicolescu AC; Zemba M; Brănişteanu CI; Brănişteanu G; Brănişteanu DC
Life (Basel); 2023 Jul; 13(8):. PubMed ID: 37629523
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
[TBL] [Abstract][Full Text] [Related]
8. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract][Full Text] [Related]
9. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
[TBL] [Abstract][Full Text] [Related]
10. Uveal melanoma: progress in molecular biology and therapeutics.
Li Y; Shi J; Yang J; Ge S; Zhang J; Jia R; Fan X
Ther Adv Med Oncol; 2020; 12():1758835920965852. PubMed ID: 33149769
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Uveal Melanoma.
Shoushtari AN; Carvajal RD
Cancer Treat Res; 2016; 167():281-93. PubMed ID: 26601868
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
14. Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma.
Amaro AA; Gangemi R; Emionite L; Castagnola P; Filaci G; Jager MJ; Tanda ET; Spagnolo F; Mascherini M; Pfeffer U; Croce M
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765842
[TBL] [Abstract][Full Text] [Related]
15. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
17. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
[TBL] [Abstract][Full Text] [Related]
18. The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
Tosi A; Cappellesso R; Dei Tos AP; Rossi V; Aliberti C; Pigozzo J; Fabozzi A; Sbaraglia M; Blandamura S; Del Bianco P; Chiarion-Sileni V; Rosato A
J Exp Clin Cancer Res; 2021 May; 40(1):154. PubMed ID: 33947438
[TBL] [Abstract][Full Text] [Related]
19. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
20. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
